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Dear Editor, 
Recently, Punzi and colleagues published a study about the role of WDR5 in breast cancer 
metastasis (Punzi et al., 2019). WDR5 is involved in epigenetic regulation complexes and has 
been reported to influence the expression of numerous genes, including N-cadherin, Snail1 and 
vimentin (Aho et al., 2019; Ford and Dingwall, 2015; Wu et al., 2011; Chen et al., 2017; Tan 
et al., 2017). Several studies suggested WDR5 as a therapeutic target (Ye et al., 2019a, b; Mac-
donald et al., 2019; Aho et al., 2019; Zhang et al., 2018; Lu et al., 2018). In their present work, 
Punzi and colleagues report that downregulation of WDR5 by shRNA in breast cancer cells 
antagonizes the epithelial-to-mesenchymal transition through re-differentiation and reduces 
metastasis in a mouse model (Punzi et al., 2019). Moreover, an association of high WDR5 
expression with shorter metastasis-free survival was observed in a cohort of breast cancer pa-
tients (Punzi et al., 2019). A further important finding of this study is that WDR5 activates 
TGFβ in breast cancer and that targeting the WDR5-TGFβ axis by a small molecular inhibitor 
reduces the migratory potential of breast cancer cells. Metastasis of breast cancer is a complex 
process (Loi et al., 2019; von Minckwitz et al., 2019; Gogiashvili, 2018; Stoeber, 2017). Be-
sides epithelial-to-mesenchymal transition, genes involved in proliferation (Schmidt et al., 
2018), immune cell infiltration (Schmidt et al., 2012, 2018; Heimes et al., 2017a, b; Godoy et 
al., 2014), oxidative stress response (Cadenas et al., 2010, 2014, 2019; Hellwig et al., 2016) 
and inflammatory factors (Mattsson et al., 2015; Sicking et al., 2014) are of relevance; also key 
enzymes of phosphocholine metabolism have been shown to control breast and ovarian cancer 
metastasis (Marchan et al., 2017; Stewart et al., 2012). It will be interesting to learn in the next 
years, whether WDR5 targeting compounds can be identified that have a perspective to be 
tested in clinical studies.  
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